| Page 16 | Aplastic Anemia and MDS International Foundation

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome

Author(s): 
de Montalembert M, Ribeil JA, Brousse V, Guerci-Bresler A, Stamatoullas A, Vannier JP, Dumesnil C, Lahary A, Touati M, Bouabdallah K, Cavazzana M, Chauzit E, Baptiste A, Lefebvre T, Puy H, Elie C, Karim Z, Ernst O, Rose C
Primary Author: 
de Montalembert M
Journal Title: 
PLoS One
Original Publication Date: 
Mar 2017

The risk and clinical significance of cardiac

Bone Marrow Diseases: 

Focal Adhesion Kinase as a Potential Target in AML and MDS

Author(s): 
Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak D, Mu H, Ruvolo V, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M
Primary Author: 
Carter BZ
Journal Title: 
Mol Cancer Ther
Original Publication Date: 
Mar 2017

Although overexpression/activation of focal adhesion kinase (FAK) is widely known in solid tumors to control cell growth, survival, invasion, metastasis, gene expression, and stem cell self-renewal, its expression and function in myeloid leukemia are not well investigated.

Bone Marrow Diseases: 

Self-reported sleep disturbance and survival in myelodysplastic syndromes

Author(s): 
Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA
Primary Author: 
Luskin MR
Journal Title: 
Br J Haematol
Original Publication Date: 
Mar 2017

Neither the prevalence of sleep disturbance nor its association with fatigue and overall survival (OS) are well understood for patients with

Bone Marrow Diseases: 

The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail

Author(s): 
Cogle CR, Kurtin SE, Bentley TG, Broder MS, Chang E, Megaffin S, Fruchtman S, Petrone ME, Mukherjee S
Primary Author: 
Cogle CR
Journal Title: 
Oncologist
Original Publication Date: 
Mar 2017

BACKGROUND:

Bone Marrow Diseases: 

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes

Author(s): 
Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T
Primary Author: 
Gerds AT
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Mar 2017

For patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, umbilical cord blood transplantation (UCBT) has become an acceptable alternative donor source in the absence of a matched sibling or unrelated donor.

Bone Marrow Diseases: 

Myelodysplastic Syndromes and Iron Chelation Therapy

Author(s): 
Angelucci E, Urru SA, Pilo F, Piperno A
Primary Author: 
Angelucci E
Journal Title: 
Mediterr J Hematol Infect Dis
Original Publication Date: 
Mar 2017

Over recent decades we have been fortunate to witness the advent of new technologies and of an expanded knowledge and application of chelation therapies to the benefit of patients with

Bone Marrow Diseases: